RxLedger

Iclusig (Ponatinib HCl) — Medicare Part D spending

Takeda Pharmace · Rank #340 by total Part D spend · CMS data year 2023

Medicare Part D spent $123,338,680 on Iclusig (Ponatinib HCl) in 2023, the #340 drug by total Part D spending out of 3,598 drugs. That worked out to about $686.96 per dosage unit, $21,413 per claim and $146,657 per beneficiary, across 5,760 claims for 841 beneficiaries. Average spending per dosage unit rose +6.1% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

Iclusig (Ponatinib HCl) spending at a glance (2023)

MetricIclusig (Ponatinib HCl)
Total Part D spending (2023)$123,338,680
Total spending (2022)$100,843,138
Year-over-year change in total spending+22.3%
Average spending per dosage unit (2023)$686.96
Change in spend per dosage unit (YoY)+6.1%
Avg annual change per dosage unit (2019-2023 CAGR)+4.7%
Average spending per claim (2023)$21,413
Average spending per beneficiary (2023)$146,657
Total claims (2023)5,760
Beneficiaries (2023)841
Total dosage units (2023)179,592
Manufacturer(s)Takeda Pharmace
National rank by total spend (of 3,598 drugs)#340

Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.

2022 vs 2023

Iclusig (Ponatinib HCl): year-over-year Medicare Part D figures. Per-claim/per-beneficiary "change" omitted because it mixes price and utilization. Source: CMS Medicare Part D Spending by Drug (data year 2023).
Metric20222023Change
Total spending$100,843,138$123,338,680+22.3%
Avg spend per dosage unit$647.40$686.96+6.1%
Avg spend per claim$21,275$21,413
Avg spend per beneficiary$136,644$146,657
Total claims4,7405,760
Beneficiaries738841

How Iclusig compares with nearby drugs

Drugs with total Part D spending closest to Iclusig (Ponatinib HCl):

Iclusig (Ponatinib HCl) and its nearest-spend peers. Source: CMS Medicare Part D Spending by Drug (data year 2023), data year 2023.
Drug (rank)Total spend 2023Per dosage unitPer-unit YoY
Iclusig (Ponatinib HCl) (this drug, #340)$123,338,680$686.96+6.1%
Carbidopa-Levodopa (Carbidopa/Levodopa) (#338)$125,111,276$0.20-5.1%
Humulin 70/30 Kwikpen (Insulin NPh Hum/Reg Insulin Hm) (#339)$124,346,168$25.46+0.4%
Valacyclovir (Valacyclovir HCl) (#341)$121,564,610$1.04-12.4%
Divalproex Sodium ER (Divalproex Sodium) (#342)$120,375,972$0.93-19.4%
Buprenorphine (#343)$119,900,450$80.07-2.3%

Frequently asked questions

How much does Medicare Part D spend on Iclusig?

Medicare Part D spent $123,338,680 on Iclusig (Ponatinib HCl) in 2023 (the latest CMS data year), across 5,760 claims for 841 beneficiaries. That ranks #340 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.

What is the average spending per dosage unit for Iclusig?

In 2023, the weighted average Medicare Part D spending per dosage unit for Iclusig (Ponatinib HCl) was $686.96. Compared with 2022 it rose +6.1%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.

Who makes Iclusig?

CMS attributes Iclusig (Ponatinib HCl) to Takeda Pharmace in the 2023 Part D spending file. Average spending per claim was $21,413 and per beneficiary $146,657.

Is the Iclusig figure the price I pay?

No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.

Keep exploring

Source & what this means

Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.

Last updated: 2026-06-20